


# Accepted Manuscript



Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder

Paul Gringras, MD, MBA, Tali Nir, DVM, John Breddy, MSc, Anat Frydman-Marom, PhD, Robert L. Findling, MD, MBA

PII: S0890-8567(17)31672-6

DOI: [10.1016/j.jaac.2017.09.414](https://doi.org/10.1016/j.jaac.2017.09.414)

Reference: JAAC 1959

To appear in: *Journal of the American Academy of Child & Adolescent Psychiatry*

Received Date: 13 July 2017

Revised Date: 28 August 2017

Accepted Date: 3 September 2017

Please cite this article as: Gringras P, Nir T, Breddy J, Frydman-Marom A, Findling RL, Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder, *Journal of the American Academy of Child & Adolescent Psychiatry* (2017), doi: 10.1016/j.jaac.2017.09.414.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## **Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children With Autism Spectrum Disorder**

RH: Pediatric PR Melatonin for Sleep in ASD

Paul Gringras, MD, MBA; Tali Nir, DVM; John Breddy, MSc; Anat Frydman-Marom, PhD; Robert L. Findling, MD, MBA

Supplemental material cited in this article is available online.

Accepted September 11, 2017

Dr. Gringras is with Children's Sleep Medicine, Evelina London Children's Hospital, Guy's and St Thomas', London. Drs. Nir and Frydman-Marom are with Neurim Pharmaceuticals Ltd, Tel Aviv, Israel. Mr. Breddy is with Pharmastat Consulting Ltd, Canterbury, UK. Dr. Findling is with Kennedy Krieger Institute/Johns Hopkins University, Baltimore, MD.

The study was funded by Neurim Pharmaceuticals.

Mr. Breddy served as the statistical expert for this research and was paid by Neurim Pharmaceuticals.

The authors would like to thank the study participants and their families for their cooperation and commitment. They thank all members of the trial team for their active contribution. They express their sincere gratitude to Amnon Katz, PhD, of the University of Jerusalem, for his help with the study design and research and Shiri Shahmoon, PhD, of the University of Tel-Aviv, for her help with the conduct of the study, data collection, and analysis. Moreover, a sincere gratitude to all investigators that participated in the study: Beth Malow, MD, MS, of Vanderbilt University Department of Neurology, Nashville, TN; Athanasios Maras, MD, PhD, of Yulius Mental Health Organization, Barendrecht; Roshan Raja, DO, of the Clinical Research Center of Nevada; Markku Partinen, MD, PhD, of Päijät-Häme Central Hospital, Helsinki; Amanda Bennett, MD, MPH, of Children's Hospital of Philadelphia; Samantha Bostrom, MD, of Ericksen Research & Development, Clinton, UT; Karen Hillock, MD, Lake Mary Pediatrics, FL; Carmen Schroder, MD, PhD, of Strasbourg University Hospital Department of Child Psychiatry and Neurology; Raun Melmed, MD, of Southwest Autism Research & Resource Center, Scottsdale, AZ; Lawrence Ginsberg, MD, Red Oak Psychiatry Association, Houston, TX; Thomas Challman, MD, Geisinger Health Systems, Union County, PA; Catherine Hill, MD, University Hospital Southampton NHS Foundation Trust; Megan Thomas, MD, PhD, Blackpool Victoria Hospital NHS Trust; Marcel G. Smits, MD, PhD, Ziekenhuis Gelderse Vallei, Willy Brandtlaan; Jerry

Download English Version:

<https://daneshyari.com/en/article/6795739>

Download Persian Version:

<https://daneshyari.com/article/6795739>

[Daneshyari.com](https://daneshyari.com)